David H. Ilson

20.0k total citations · 1 hit paper
276 papers, 7.9k citations indexed

About

David H. Ilson is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, David H. Ilson has authored 276 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 216 papers in Pulmonary and Respiratory Medicine, 154 papers in Surgery and 103 papers in Oncology. Recurrent topics in David H. Ilson's work include Gastric Cancer Management and Outcomes (190 papers), Esophageal Cancer Research and Treatment (128 papers) and Lung Cancer Treatments and Mutations (59 papers). David H. Ilson is often cited by papers focused on Gastric Cancer Management and Outcomes (190 papers), Esophageal Cancer Research and Treatment (128 papers) and Lung Cancer Treatments and Mutations (59 papers). David H. Ilson collaborates with scholars based in United States, Japan and Germany. David H. Ilson's co-authors include David P. Kelsen, Eileen M. O’Reilly, David P. Kelsen, Gary K. Schwartz, Bruce D. Minsky, Geoffrey Y. Ku, Manjit S. Bains, Leonard B. Saltz, Manish A. Shah and Marinela Capanu and has published in prestigious journals such as Nature, The Lancet and Journal of Clinical Oncology.

In The Last Decade

David H. Ilson

267 papers receiving 7.7k citations

Hit Papers

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-posi... 2023 2026 2024 2025 2023 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
    2023 342 citations Kohei Shitara, Florian Lordick et al. profile →

Peers

David H. Ilson
Sachio Fushida Japan
Simon Law Hong Kong
Mario Sarbia Germany
Masahiko Koike Japan
Tomoyuki Kato Japan
Yasushi Omuro Japan
Mitsuro Kanda Japan
Jianming Xu China
Gennaro Galizia Italy
Heinz Becker Germany
Sachio Fushida Japan
David H. Ilson
Citations per year, relative to David H. Ilson David H. Ilson (= 1×) peers Sachio Fushida

Countries citing papers authored by David H. Ilson

Since Specialization
Citations

This map shows the geographic impact of David H. Ilson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David H. Ilson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David H. Ilson more than expected).

Fields of papers citing papers by David H. Ilson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David H. Ilson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David H. Ilson. The network helps show where David H. Ilson may publish in the future.

Co-authorship network of co-authors of David H. Ilson

This figure shows the co-authorship network connecting the top 25 collaborators of David H. Ilson. A scholar is included among the top collaborators of David H. Ilson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David H. Ilson. David H. Ilson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Moy, Andrea P., Stephen W. Dusza, Alison J. Moskowitz, et al.. (2025). Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series. The Oncologist. 30(9). 2 indexed citations
2.
Klempner, Samuel J., Roberto Pazo-Cid, Sara Lonardi, et al.. (2025). Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study. PubMed. 7. 100131–100131. 4 indexed citations
3.
Suman, Shalabh, Joanne F. Chou, Peter M. Krein, et al.. (2024). Association of ERBB2 extrachromosomal DNA (ecDNA) with first-line HER2-targeted treatment outcomes in advanced esophagogastric adenocarcinoma (EGC).. Journal of Clinical Oncology. 42(16_suppl). 4041–4041. 3 indexed citations
4.
5.
6.
Klempner, Samuel J., Keun‐Wook Lee, Kohei Shitara, et al.. (2023). ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research. 29(19). 3882–3891. 44 indexed citations
7.
Yu, Kenneth H., Jennifer Park, Ghassan K. Abou‐Alfa, et al.. (2022). Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer. Cancer. 128(15). 2958–2966. 7 indexed citations
8.
Jabbour, Salma K., Terence M. Williams, Mutlay Sayan, et al.. (2020). Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies. JNCI Journal of the National Cancer Institute. 113(6). 665–679. 7 indexed citations
9.
Ilson, David H.. (2020). Pembrolizumab for Microsatellite-Instability–High Advanced Colorectal Cancer. Journal watch. 2020. 109 indexed citations
10.
Won, Elizabeth, Walid K. Chatila, Jaclyn F. Hechtman, et al.. (2019). Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. Clinical Cancer Research. 25(13). 3811–3817. 14 indexed citations
11.
Greally, Megan, Joanne F. Chou, Walid K. Chatila, et al.. (2019). Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. Clinical Cancer Research. 25(20). 6160–6169. 75 indexed citations
12.
Ilson, David H.. (2019). Maintenance Olaparib for Germline. Journal watch. 2019. 8 indexed citations
13.
Ilson, David H.. (2018). The 2018 Gastrointestinal Cancers Symposium. Journal watch. 2018.
14.
Dika, Imane El & David H. Ilson. (2018). Current and future therapies for targeting HER2 mutations in gastrointestinal cancer. Expert Review of Anticancer Therapy. 18(11). 1085–1092. 7 indexed citations
15.
Won, Elizabeth, et al.. (2014). HER2 Directed Therapy for Gastric/Esophageal Cancers. Current Treatment Options in Oncology. 15(3). 395–404. 19 indexed citations
16.
Ilson, David H.. (2010). Combination Chemotherapy for Advanced Pancreatic Cancer. Journal watch. 2010.
17.
Ilson, David H.. (2008). Stage II Colon Cancer: To Treat or Not to Treat?. Journal watch. 2008. 2 indexed citations
18.
Bains, Manjit S., Alexander Stojadinovic, Bruce D. Minsky, et al.. (2002). A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results. Journal of Thoracic and Cardiovascular Surgery. 124(2). 270–277. 56 indexed citations
19.
Ilson, David H. & David P. Kelsen. (1996). Management of esophageal cancer.. PubMed. 10(9). 1385–8. 11 indexed citations
20.
Ilson, David H., Paul F. Torrence, & J Vilček. (1986). Two Molecular Weight Forms of Human 2′,5′-Oligoadenylate Synthetase Have Different Activation Requirements. Journal of Interferon Research. 6(1). 5–12. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sachio Fushida Breakdown of academic impact, for papers by Simon Law Breakdown of academic impact, for papers by Mario Sarbia Breakdown of academic impact, for papers by Masahiko Koike Breakdown of academic impact, for papers by Tomoyuki Kato Breakdown of academic impact, for papers by Yasushi Omuro Breakdown of academic impact, for papers by Mitsuro Kanda Breakdown of academic impact, for papers by Jianming Xu Breakdown of academic impact, for papers by Gennaro Galizia Breakdown of academic impact, for papers by Heinz Becker
Rankless by CCL
2026